About this Journal Submit a Manuscript Table of Contents
Oxidative Medicine and Cellular Longevity
Volume 2013 (2013), Article ID 146860, 10 pages
http://dx.doi.org/10.1155/2013/146860
Review Article

Adenine Nucleotide Translocase, Mitochondrial Stress, and Degenerative Cell Death

Department of Biochemistry and Molecular Biology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA

Received 10 May 2013; Revised 14 June 2013; Accepted 24 June 2013

Academic Editor: Sergio Giannattasio

Copyright © 2013 Yaxin Liu and Xin Jie Chen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Mitochondria are intracellular organelles involved in ATP synthesis, apoptosis, calcium signaling, metabolism, and the synthesis of critical metabolic cofactors. Mitochondrial dysfunction is associated with age-related degenerative diseases. How mitochondrial dysfunction causes cell degeneration is not well understood. Recent studies have shown that mutations in the adenine nucleotide translocase (Ant) cause aging-dependent degenerative cell death (DCD) in yeast, which is sequentially manifested by inner membrane stress, mitochondrial DNA (mtDNA) loss, and progressive loss of cell viability. Ant is an abundant protein primarily involved in ADP/ATP exchange across the mitochondrial inner membrane. It also mediates basal proton leak and regulates the mitochondrial permeability transition pore. Missense mutations in the human Ant1 cause several degenerative diseases which are commonly manifested by fractional mtDNA deletions. Multiple models have been proposed to explain the Ant1-induced pathogenesis. Studies from yeast have suggested that in addition to altered nucleotide transport properties, the mutant proteins cause a global stress on the inner membrane. The mutant proteins likely interfere with general mitochondrial biogenesis in a dominant-negative manner, which secondarily destabilizes mtDNA. More recent work revealed that the Ant-induced DCD is suppressed by reduced cytosolic protein synthesis. This finding suggests a proteostatic crosstalk between mitochondria and the cytosol, which may play an important role for cell survival during aging.

1. Introduction

Mitochondria are essential organelles as they produce most of ATP to support cellular activities, synthesize critical metabolic factors such as heme and iron-sulfur clusters, and are involved in lipid and phospholipid metabolism as well as calcium signalling [1]. Mitochondria also play an important role in determining the fate of cell via their involvement in cell death. Cell death can be classified into different categories. According to the morphological appearance, for instance, cells undergo death via necrosis (accidental cell death or programmed necrosis), apoptosis, or aberrant autophagy, all with significant involvement of mitochondria. In yeast, mitochondria-mediated apoptosis is believed to execute with some steps common to the mammalian cells. Oxidative burst, mitochondrial fragmentation, the collapse of mitochondrial membrane potential, and the release of cytochrome are commonly observed in apoptotic yeast cells [2, 3].

In addition to the relatively acute forms of cell death aforementioned, mitochondrial function also progressively deteriorates during aging, which leads to cellular senescence. It is conventionally thought that mitochondria contribute to aging mainly through the overproduction of reactive oxygen species (ROS) and underproduction of ATP in aged cells. Interestingly, recent studies have suggested that mitochondria may overcome these stresses and promote cell survival by altered cellular signalling [47]. In this review, we will present a novel form of mitochondria-induced cell death in yeast cells, tentatively referred as degenerative cell death (DCD). DCD is characterized by mitochondrial inner membrane stress, mtDNA damage, and progressive loss of cell viability. The key feature of DCD, which is distinct from the currently known forms of cell death in yeast (e.g., apoptosis and necrosis), is the loss of mtDNA which cannot be tolerated by cells with compromised inner membrane integrity. This was revealed by studying some mutant forms of adenine nucleotide translocase, which causes aging-dependent cellular degeneration. These studies may provide new perspectives for the mechanism of mitochondrial degeneration, in addition to the well-established roles of oxidative stress and mitochondrial quality control which contribute to aging.

2. Physiological Roles of Adenine Nucleotide Translocase

Adenine nucleotide translocase (or adenine nucleotide translocator or Ant) is the most abundant protein in mitochondria, accounting for up to 10% of total mitochondrial protein content [8]. It is encoded by the nuclear DNA, synthesized in cytosol, imported into mitochondria, and finally inserted into the inner membrane [911]. Ant belongs to the mitochondrial carrier family (MCF) proteins, a class of proteins that plays an important role in the transport of metabolites and cofactors across the mitochondrial inner membrane [12, 13]. The primary function of Ant is to catalyze ADP/ATP exchange across the inner membrane. Under respiring conditions, ATP4− generated by oxidative phosphorylation is exported to the cytosol for use in cellular activities and ADP3− is imported into the mitochondrial matrix for continuous ATP synthesis. Ant is therefore an ADP3−/ATP4− exchanger. During this strict exchange process, one net negative charge is moved from the matrix to the cytosol, resulting in a charge differential that is driven by membrane potential across the mitochondrial inner membrane [14]. Ant binds to its substrates with relatively low affinity, while its high abundance can compensate for the inefficient transport. Ant also has an intrinsic property of mediating proton leakage [8]. In addition to its involvement in a fatty acid-dependent proton leakage pathway, it accounts for 1/2 to 2/3 of the basal proton conductance through an unknown mechanism. Hence, Ant can result in mild uncoupling and decrease efficiency of ATP synthesis.

The Ant protein has multiple isoforms in different species. In humans, there are four isoforms that have distinct tissue-specific expression patterns. Ant1 is predominantly expressed in postdifferentiated tissues such as heart and skeletal muscle [15]. Ant2 is more abundant in certain proliferating tissues [16, 17]. Ant3 is ubiquitously expressed and Ant4 is specifically expressed in the testis [18]. Only three isoforms of Ant have been found in mouse (Ant1, 2, and 4). Mouse Ant1 is a heart/skeletal muscle specific isoform, while mouse Ant2 is highly expressed in all tissues except muscle. Mouse Ant4 is expressed primarily in testis as in humans [15, 18]. Yeast contains three isoforms of ADP/ATP carrier (Aac), which are homologues of Ant in humans. Aac2 is the major ADP/ATP carrier in aerobically grown yeast cells [19].

Like other members in MCF, Ant has three repeats of a ~100 amino acid sequence and each repeat contains two transmembrane domains that form alpha helices [20, 21]. Biochemical characterization of Ant benefited from two specific inhibitors of Ant, bongkrekic acid (BA) and carboxyatractyloside (CATR). Both of the inhibitors bind with the stoichiometry of one inhibitor per two molecules. BA binds the matrix side of Ant and CATR binds on the intermembrane space side [2224]. The transition between CATR and BA conformations is suggested to be the structural switch involved in ADP/ATP transport [19]. The crystal structure of bovine Ant complexed with CATR revealed the organization of six transmembrane domains with both N- and C-termini extending into the intermembrane space [25] (Figure 1). All the transmembrane domains are α-helices, which are tilted and form a cavity with the opening toward the intermembrane space. Three kinks are introduced by proline residues between two helices on the matrix side of Ant, which may act as hinges to facilitate the opening and closing of the nucleotide translocation channel [25]. Recent study of yeast Aac2 using hydrogen/deuterium exchange-mass spectrometry showed that the BA-bound Aac2 is structurally different from the CATR-bound form. The BA conformation has better solvent accessibility from the matrix side [26, 27]. Ant has the RRRMMM signature sequence, which is absent from other mitochondrial carriers. This motif spans over the thinnest part of the channel and the arginine residues are essential for attracting the negatively charged nucleotides to facilitate transport [25, 28, 29]. In addition to the arginine residues, the methionine triplet also contributes to nucleotide translocation or binding [27].

146860.fig.001
Figure 1: Projected localization of A90, L98, A114, A123, and the arginine triplet on the crystal structure of bovine Ant1 in the cytosolic conformation bound by CATR (yellow) [25]. The corresponding amino acids in yeast Aac2 are also indicated. R252, R253, and R254 in yeast correspond to R234, R235, and R236 in the bovine protein. IMS, intermembrane space; M, matrix.

It has been debated whether Ant functions as a monomer or a dimer. A dimeric structure was first suggested by native gel electrophoresis, ultracentrifugation, neutron scattering, and cross-linking studies [3035]. In the dimer model, the C terminus of one monomer is predicted to be close to the N terminus of a second monomer [3638]. However, more recent reports suggested that Ant may be present in a monomeric form. The crystal structure of bovine Ant1 was solved as a monomer [25]. The study using differential tagging showed that the yeast Aac2 is a monomer in mild detergents because tagged Aac2 does not form dimers with untagged Aac2 [39]. Other techniques such as analytical ultracentrifugation, small-angle neutron scattering and electron cryomicroscopy also suggested that Ant more likely functions as monomers (reviewed in [40]).

Ant may also affect the mitochondrial permeability transition pore (mPTP) on the inner membrane, but its exact role in this activity has been highly debated [4144]. Elevated Ca2+ and other factors are involved in the stimulation of mPTP opening followed by increased permeability of solutes across the inner membrane, which results in the dissipation of membrane potential, mitochondrial swelling, and finally cell death through apoptosis or necrosis. It has also been documented that mPTP plays a role in mediating organismal aging [45]. Early studies suggested Ant as a critical component of mPTP, along with voltage-dependent anion channel (VDAC) in the outer membrane and cyclophilin D (CyPD) in the matrix [46, 47]. However, Kokoszka et al. inactivated the two Ant isoforms in mouse and still detected the opening of mPTP triggered by Ca2+, suggesting that Ant is not essential for mPTP [48]. Ant still plays a role in the regulation of mPTP since more Ca2+ are required to activate the mPTP and the Ant ligands no longer regulate the mPTP. The very recent studies defined the mPTP as the dimers of the FoF1-ATP synthase that is regulated by CyPD [49] and the c subunit of the enzyme appears to be critical for permeability transition [50]. Given that adenine nucleotides are the substrates of the ATP synthase, Ant may contribute to mPTP regulation by affecting nucleotide levels in the matrix where the F1-ATPase sector of the ATP synthase is located. It has been reported in yeast that loss of Ant (or Aac) protects cells from acetic acid and diamide-induced mitochondrial outer membrane permeabilization, mitochondrial degradation, and apoptosis [5153]. Interestingly, this was proposed to involve mPTP probably via an activity independent of nucleotide translocation.

3. Altered Ant Expression and Human Diseases

Given the importance of Ant to mitochondrial physiology, mutations or altered expression of Ant has been found to be associated with a growing list of human diseases (Table 1). In all the four Ant isoforms, Ant1 is so far the only one found to directly cause mitochondrial diseases. Early work has shown that ANT1−/− mice presented overproliferation of mitochondria in skeletal and heart muscles, ragged-red fibers (fibers that have a ragged contour and an accumulation of red staining material which is associated with proliferation of abnormal mitochondria), cardiac hypertrophy, exercise intolerance, lactic acidosis, and deficiency in coupled respiration in mitochondria [54]. In humans, deficiency in Ant1 is associated with Senger’s syndrome, an autosomal recessive disease characterized by hypertrophic cardiomyopathy, mitochondrial myopathy, lactic acidosis, and congenital cataracts [55]. Although depletion of Ant1 in heart and muscle tissues has been proposed to be the primary cause of the Senger’s syndrome, no mutations have been found in ANT1. It has been speculated that the transcription, translation, or posttranslational modification of Ant1 may be affected [56]. Recently, two nonsense mutations in the gene encoding the mitochondrial acylglycerol kinase (AGK) were identified from a patient with typical symptoms of Senger’s syndrome [57]. AGK is a multisubstrate lipid kinase involved in phospholipid metabolism. The loss of AGK may result in the decrease of Ant by affecting its biogenesis. In addition to Senger’s syndrome, loss of Ant1 due to a homozygous null mutation also causes cardiomyopathy, and the severity of the cardiac disease correlates with the mtDNA haplogroup. Patients with the haplogroup U mtDNAs are more affected than those having the haplogroup H [58]. Overall, deficiency in Ant1 expression and biogenesis would be expected to cause not only reduced ATP output but also oxidative damage because of FoF1-ATP synthase stalling, increased electron leak, and ROS production.

tab1
Table 1: Ant-associated human diseases.

In contrast to Ant1 deficiency, overexpressed Ant1 may contribute to the pathogenesis of other diseases such as facioscapulohumeral muscular dystrophy (FSHD). FSHD is a highly variable autosomal dominant neuromuscular disorder. Patients with FSHD suffer from cumulative progression of muscle weakness in the face, feet, shoulders, and hips, along with occasionally sensorineural hearing loss [59]. Deletions of the D4Z4 repeated sequences on chromosome IV are commonly found in FSHD patients, which may lead to transcriptional derepression of nearby genes including ANT1, FRG1, FRG2, and DUX4 [6063]. Overexpression of FRG1, a gene involved in pre-mRNA splicing, and not ANT1, was proposed to be responsible for FSHD [64]. Other studies instead proposed that expression of DUX4 is critical for FSHD pathogenesis [63]. Nevertheless, recent studies have also reported the overexpression of Ant1 and increased oxidative stress in FSHD muscles [65]. These observations suggest that Ant1 may play a role in the pathogenesis of FSHD.

Although the sequence identity between the Ant isoforms is as high as 70%~90% [66], their nucleotide transport properties may differ and altered expression of these isoforms could have different metabolic consequences. For example, ANT2 is upregulated in hormone-dependent cancers. Brenner et al. showed that ANT2 mRNA is significantly elevated in primary tissues derived from patients with breast, uterus, ovary, lung, thyroid gland bladder, and testis cancers [67]. Unlike healthy cells, cancer cells intensively employ glycolysis and have reduced oxidative phosphorylation (OXPHOS) to adapt to the intratumoral hypoxic conditions [68]. It has been known in yeast that when cells are severely compromised in mitochondrial function (e.g. ρo cells), the mitochondrial membrane potential is maintained through reversed nucleotide transport by the ADP/ATP carrier. ATP is imported into the matrix, where it is recycled back to ADP as long as an active F1-ATPase is present. ADP is then exported into the cytosol. This reversal ADP/ATP exchange is critical for mitochondrial biogenesis and cell viability under severe mitochondrial damage conditions [6972]. By analogy, cancer cells are speculated to import glycolytically produced ATP into mitochondrial matrix via Ant2 [73]. The human FoF1-ATPase may hydrolyze ATP to ADP that facilitates the electrogenic / exchange [74]. Given the key role of Ant2 in cancer metabolism, it may be used as a potential target for cancer therapy.

4. Dominant Mutations in Ant1 and Human Diseases

Missense mutations in Ant1 have been found to cause several human diseases. One of them is autosomal dominant Progressive External Ophthalmoplegia (adPEO), which is characterized by late or adult onset muscle weakness (especially in eye muscles), exercise intolerance, sensory ataxia, hypertrophic cardiomyopathy, and myopathy [7577]. Multiple mtDNA deletions and mild defects in the respiratory complexes were detected in affected tissues. adPEO is also caused by specific missense mutations in the mitochondrial twinkle helicase or in the mtDNA specific polymerase, Polγ [78, 79], which are directly involved in mtDNA replication. Moreover, a total of five Ant1 missense mutations have been reported in one sporadic and four familial cases of adPEO. Most of these mutations occur in highly conserved amino acids: Ala90, Leu98, Asp104, Ala114 and Val289 [7577, 80]. In addition to adPEO, the A123D missense mutation has been identified in a homozygous patient, which is manifested by slow progressive mitochondrial myopathy and cardiomyopathy, but not opthalmoplegia [81]. All those six mutable amino acids except Val289 locate in the helix 2-loop-helix 3 region (Figure 1), which is suggested to undergo dynamic structural changes during nucleotide transport [82]. A later study has shown that the sporadic V289M mutation is accompanied with a mutation in POLG1, the gene encoding the large subunit of Polγ [83]. Thus, the contribution of this particular Ant1 mutant allele to the pathogenesis is uncertain when present at a heterozygous state.

5. Models for Human Diseases Caused by Gain-of-Function Ant1 Mutations

Several model systems have been developed to study the pathogenic mechanism of human diseases caused by the gain-of-function mutations in Ant1 (Figure 2). Kaukonen et al. first introduced the adPEO-type Aac2A128P allele, equivalent to human Ant1A114P, in haploid yeast strains that are disrupted of the AAC1 and AAC2 genes [75]. Cells expressing the mutant allele showed a growth defect on nonfermentable carbon sources. The data suggested that the A128P mutation may affect ADP/ATP translocation. This may lead to imbalanced adenine nucleotides, altered intramitochondrial dATP levels in the matrix, and, ultimately, multiple mtDNA deletions.

146860.fig.002
Figure 2: Proposed models for the pathogenic mechanisms of human diseases induced by dominant missense Ant1 mutations. These models predict that the mutant proteins (1) are defective in targeting onto the mitochondrial inner membrane; (2) are defective in nucleotide transport which sequentially causes ATP overaccumulation in the matrix, electron transport chain stalling, membrane hyperpolarization, increased ROS production, and oxidative damage; (3) are engaged in the futile ATPcytosol/ATPmatrix exchange which leads to matrix nucleotide imbalance and mtDNA deletions; (4) reverse the ADPcytosol/ATPmatrix exchange under normal conditions which also leads to ATP overaccumulation in the matrix; and (5) cause proteostatic stress on the mitochondrial inner membrane.

In a subsequent study, the human ANT1 gene was expressed in a yeast mutant disrupted of all the three AAC genes [84]. The and variants were introduced to evaluate their efficiency in promoting respiratory growth. The complementation test showed that in contrast to the wild type ANT1, the two mutant alleles failed to restore cell growth on the nonfermentable lactate medium. Interestingly, the mutant proteins were not detected in the mitochondrial fraction of yeast cells by atractyloside binding and immunodecoration assays, whereas the RNA levels of the mutant ANT1 were comparable with the wild type. This observation led to the speculation that and may not be imported into mitochondria in human diseases.

As the primary function of Ant is to promote adenine nucleotide transport, the simplest explanation for Ant1-induced adPEO is that the mutant proteins are defective in the transport activity. The dominant phenotypes can only be explained by assuming that Ant1 operates in a dimeric form or that the heterozygous cells are haploinsufficient for the protein. Fontanesi et al. found that the growth of haploid yeast cells expressing only , , or was severely affected on nonfermentable carbon sources [85]. In addition, cytochrome content, cytochrome oxidase activity, and mitochondrial respiration were all decreased in the mutant cells. In heteroallelic haploid cells, in which the wild type and mutant aac2 were coexpressed, the level of mitochondrial respiration remained low. This is consistent with the dominant nature of adPEO pathogenesis. The authors also measured the transport properties of , , and by determining ATP homoexchange rate, ADP homoexchange rate, and ADP/ATP heteroexchange rate in reconstituted proteoliposomes in vitro. Interestingly, all the three mutant proteins still retain a robust transport activity for ATP and ADP. However, the mutant proteins preferentially import ATP over ADP. The authors proposed that this may lead to a futile ATP/ATP homoexchange instead of the physiologically productive ATPmatrix/ADPcytosol heteroexchange mode. This may ultimately result in elevated mitochondrial ATP level. One possible consequence of ATP/ADP imbalance is the increased dATP level, which in turn affects the accuracy of mtDNA replication [85]. However, it is important to note that dATP is likely imported directly from cytosol in yeast rather than converted from ADP or ATP in the mitochondrial matrix. Whether the altered transport properties have physiological implications especially in heterozygous diploid cells needs to be further evaluated.

Another model proposed by Kawamata et al. also involves a possible alteration to the nucleotide transport property of Ant1. These authors evaluated the effect of and on mitochondrial function in the mouse C2C12 myotube cells [86]. Exogenous Ant1 mutant proteins were confirmed to be localized on the mitochondrial inner membrane. However, no significant differences on oxygen consumption, ATP synthesis, total cellular ATP level, CATR sensitivity, or mtDNA content were detected between the cells expressing the mutant and wild type Ant1. Of interest, mitochondria of A114P-, but not V289M-, expressing myotubes were found to have a reduced ADP/ATP exchange rate and a slightly smaller ADP-induced depolarization. Reduced ADP-induced depolarization suggests a defect in ADP translocation. In addition, cells expressing the A114P and V289M alleles showed abnormal translocator reversal potential. They were switched to the / exchange mode at a higher membrane potential. It was speculated that mutant Ant1 is more prone to invert the direction of ADP/ATP exchange even at the membrane potential still in the physiological range for ATP synthesis. This may lead to increased ATP and nucleotide imbalance in the mitochondrial matrix. Importantly, this phenotype is not caused by loss of function, because the ADP/ATP exchange rate in Ant1-silenced myotubes showed different properties.

Whether altered nucleotide transport is the pathogenic mechanism of Ant1-induced diseases is still inconclusive. The study of in yeast provided some useful information. is equivalent to the human mutation, which does not cause ophthalmoplegia in a homozygous patient but share other common symptoms with adPEO patients including hypertrophic cardiomyopathy, mild myopathy, ragged muscle fibers, exercise intolerance, lactic acidosis, and accumulation of mtDNA deletions. Yeast cells expressing only are respiratory deficient as they do not grow on nonfermentable carbon sources [81]. The in vitro reconstitution assay showed that completely lacks the ability to transport ATP or ADP. This provides strong evidence that mtDNA deletions in the patient arise independently of nucleotide transport. The yeast cells have a low viability, which is suppressed by ROS scavengers. This supports the idea that the mutant is vulnerable to oxidative stress and anti-ROS treatments may be a potential therapeutic strategy [81].

6. The Proteostatic Stress Model

More recent studies in yeast supported the idea that aac2 alleles resembling the human pathogenic ant1 mutations may interfere with general mitochondrial biogenesis in a dominant manner [87, 88]. It was shown that yeast cells coexpressing the mutant aac2 alleles and the wild type AAC2 exhibit reduced cellular respiration, suggesting that the electron transport chain is severely damaged. In a yeast strain that overexpresses , mitochondria showed dramatic depolarization as well as swelling and disintegration of mitochondria. More importantly, when cells expressing only one chromosomally integrated copy of were incubated at 25°C, cell growth is inhibited on glucose medium. Yeast is well known for its ability to grow on fermentable carbon sources without mitochondrial respiration. The growth inhibition strongly suggests that expression of the mutant Aac2 interferes with general mitochondrial biogenesis. Furthermore, when two copies of , , , or were intergraded into the genome, the frequencies of respiratory-deficient petite colonies on glucose medium are greatly increased. This observation recapitulates the mtDNA instability phenotype in human adPEO. Petite frequencies are further increased when cells are grown on raffinose plus galactose medium which stimulates respiration. Concomitantly, cell viability is dramatically reduced.

Additional phenotypes supported the model that expression of the mutant Aac2 causes general mitochondrial damage [88]. Firstly, the expression of mtDNA-encoded protein, Cox2p, is reduced in the aac2 mutants. Secondly, yeast cells expressing the four aac2 mutant alleles are intolerant to ρo condition. The ρo-lethality phenotype is an indication of low membrane potential. Cells lose viability when membrane potential is further reduced by the loss of mtDNA. Thirdly, these aac2 mutants are also hypersensitive to the chemical uncoupler CCCP, consistent with the low membrane potential model. Fourthly, cells coexpressing the mutant aac2 and wild type alleles have a diminished respiratory control ratio (RCR), which indicates uncoupled respiration. These data support the model that the mutant Aac2 may cause general stress on the membrane, which leads to defects in respiratory complex biogenesis, membrane uncoupling, loss of ion homeostasis, and the inhibition of cell growth.

Since completely lacks nucleotide transport activity but exhibits similar phenotypes as other mutant aac2 alleles, these results suggest that mitochondrial damage is independent of ADP/ATP exchange. Further evidence came from the analysis of the double mutants combining with mutations in the Arg252–254 triplet which mitigates adenine transport function [89]. It was found that the arginine mutations barley affects the inhibition of cell growth by the allele. Mitochondrial damage is therefore independent of nucleotide transport. In summary, the data suggested that the mutant Aac2 proteins primarily damage the inner membrane, which consequently affects mitochondrial biogenesis. The loss of mtDNA integrity is likely a consequence of membrane stress.

The global mitochondrial damage model is supported by another study from El-Khoury and Sainsard-Chanet using the filamentous fungi Podospora anserina as a model system [90]. The A114P, L98P, and V289M alleles were introduced into the P. anserina ANT1 ortholog, PaANT. The three mutant strains showed a delayed and reduced rate of germination, a slow vegetative growth rate, and other somatic and sexual defects. In P. anserina, lifespan is a good indicator of mtDNA integrity. The three mutant strains were suggested to accumulate mtDNA deletions as they showed dramatically reduced lifespan in certain mating type (mat). Interestingly, short lifespan caused by A114P and L98P mutations, but not V289M, was suppressed by the rmp1-2 allele, which is one of the two naturally occurring alleles of rmp1. The rmp1 gene is associated with the timing of death and linked to the mat locus tightly. The results indicated that the lifespan in the A114P and L98P mutants is dependent on whether it has the rmp1-1 or the rmp1-2 allele, but not the mating type. Further studies suggested that premature cell death is independent of mtDNA instability. Mutant strains also exhibited decreased ROS production and mitochondrial inner membrane potential, which could not be suppressed by the rmp1-2 allele.

Another important finding in the yeast model is that the missense aac2 alleles are all synthetically lethal with the disruption of the YME1 gene, which encodes a chaperone/protease on the inner membrane for degradation of misfolded proteins. This observation strongly suggests that proteostatic stress on the membrane may be responsible for the global mitochondrial damage and the inhibition of cell growth [88].

7. Ant Mutations Induce Degenerative Cell Death

The Chen group found that mitochondrial damage by the mutant aac2 alleles causes aging-dependent DCD [89]. When yeast cells heterozygous for were individually spotted on complete glucose medium by micromanipulation, a subfraction of cells formed barely visible microcolonies [87, 89]. The microcolonies contain 2,000~4,000 cells that fail to divide and to produce proliferating lineages. It appears that cells can divide for up to 12~13 generations before complete growth arrest. The delayed loss of the ability to proliferate is termed degenerative cell death (DCD). DCD is likely initiated by membrane stress-induced mtDNA loss (Figure 3). As the aac2 mutants are ρo-lethal, mtDNA loss therefore causes cell death. Cells can continue to divide for limited cell generations after mtDNA loss, probably reflecting either progressive accumulation of cellular factors that inhibit cell division or a dilution of mitochondrial factors that are essential for cell viability. This is supported by pedigree analysis showing that in haploid cells coexpressing AAC2 and , the degenerative mother cell consistently produces degenerative daughter cells. The daughter cells likely inherit the permanently damaged mtDNA from the mother cell which causes cell death. Interestingly, DCD caused by is aging dependent. Replicatively aged mother cells have increased DCD. Approximate half of the founding mother cells have their first degenerative daughter cells after 9~11 cell divisions [89], which is a mid-age onset given that the median lifespan of most Saccharomyces cerevisiae strains is about 25 generations.

146860.fig.003
Figure 3: Schematic diagram showing the proteostatic stress model for the pathogenic mechanism of Ant1-induced degenerative cell death. This model predicts that the mutant Ant induces proteostatic stress on the mitochondrial inner membrane, which interferes with general mitochondrial biogenesis and the maintenance of membrane potential, followed by mtDNA destabilization. The severe membrane damage and mtDNA destabilization collectively contribute to degenerative cell death. Degenerative cell death is suppressed by reduced cytosolic protein synthesis which improves global proteostasis. Stars indicate the localization of mutations.

To understand the mechanism of DCD, much effort has been invested to identify pathways that suppress the degenerative process. It was found that genetic manipulations that reduce cytosolic protein synthesis remarkably suppress DCD [89]. For instance, RPL6B encodes a component of 60S ribosomal subunit and its disruption is expected to reduce cytosolic protein synthesis. By meiotic analysis, -expressing segregants produce small and sectoring colonies indicative of DCD, whereas cells harboring both and form regular colonies as the wild type. Other genes that suppress in the same manner include GRP1 (encoding a G-protein-coupled receptor upstream of the protein kinase A pathway), REI1 (involved in ribosomal biogenesis), TOR1 and SCH9 (encoding kinases in the TOR signaling pathway). DCD is also suppressed by cycloheximide, an inhibitor of cytosolic protein synthesis, which further supports the model that reduced cytosolic protein synthesis suppresses mitochondrial degeneration and DCD [89]. In P. anserina, premature cell death and mtDNA instability induced by ANT1 mutations are suppressed by a mutation in the AS1 gene encoding a ribosomal protein [90].

Expression of the allele shortens the replicative lifespan of yeast cells in a dominant-negative manner, and the shortened lifespan is corrected by the disruption of RPL6B, REI1, and SCH9 [89]. This observation supports an epistatic interaction between mitochondrial inner membrane stress and cytosolic protein homeostasis in the control of replicative lifespan. A role of mitochondria in aging and lifespan control is well established [91, 92]. It has been extensively documented that adaptive mitochondria-to-nucleus signaling via the retrograde-response pathway increases cell’s lifespan (for review, see [93]). It remains unknown whether -induced mitochondrial damage triggers an adaptive adjustment of cytosolic protein homeostasis during replicative aging.

8. Conclusions and Prospects

The pathogenic mechanism of Ant1-induced human diseases is not fully settled. Studies using yeast cells have indicated that the mutant Ant1 may gain a novel property to affect global mitochondrial biogenesis in addition to a potential effect on nucleotide homeostasis. The mutant Ant either directly uncouples the respiration or indirectly compromises protein homeostasis on the membrane which subsequently affects mitochondrial biogenesis. The severe inner membrane damage is manifested by DCD. DCD is initiated by inner membrane damage, followed by mtDNA loss and progressive loss of cell viability because of ρo-lethality. These characteristics distinguish it from currently described forms of cell death in yeast including apoptosis and necrosis. Ant-induced DCD is suppressed by reduced cytosolic protein synthesis. This finding strongly suggests that proteostatic stress may play a role in cell degeneration (Figure 3). Future studies are required to understand the mechanism of Ant-induced membrane stress and its contribution to aging-dependent cell degeneration.

Abbreviations

Aac: ADP/ATP carrier
adPEO: Autosomal dominant Progressive External Ophthalmoplegia
AGK: Acylglycerol kinase
Ant: Adenine nucleotide translocase
BA: Bongkrekic acid
CATR: Carboxyatractyloside
CCCP: Carbonyl cyanide m-chlorophenyl hydrazone
CyPD: Cyclophilin D
DCD: Degenerative cell death
FSHD: Facioscapulohumeral muscular dystrophy
MCF: Mitochondrial carrier family
mtDNA: Mitochondrial DNA
mPTP: Mitochondrial permeability transition pore
OXPHOS: Oxidative phosphorylation
ROS: Reactive oxidative species

Conflict of Interests

The authors declare that they have no financial conflict of interests.

Acknowledgments

This work was supported by the Grant AG023731 from the National Institute on Aging, National Institute of Health.

References

  1. D. C. Wallace, “Why do we still have a maternally inherited mitochondrial DNA? insights from evolutionary medicine,” Annual Review of Biochemistry, vol. 76, pp. 781–821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Eisenberg, S. Büttner, G. Kroemer, and F. Madeo, “The mitochondrial pathway in yeast apoptosis,” Apoptosis, vol. 12, no. 5, pp. 1011–1023, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Guaragnella, L. Antonacci, S. Passarella, E. Marra, and S. Giannattasio, “Hydrogen peroxide and superoxide anion production during acetic acid-induced yeast programmed cell death,” Folia Microbiologica, vol. 52, no. 3, pp. 237–240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Caballero, A. Ugidos, B. Liu et al., “Absence of mitochondrial translation control proteins extends life span by activating sirtuin-dependent silencing,” Molecular Cell, vol. 42, no. 3, pp. 390–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. X. J. Chen, “The search for nonconventional mitochondrial determinants of aging,” Molecular Cell, vol. 42, no. 3, pp. 271–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Jazwinski, “The retrograde response: when mitochondrial quality control is not enough,” Biochimica et Biophysica Acta, vol. 1833, no. 2, pp. 400–409, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Delaney, U. Ahmed, A. Chou et al., “Stress profiling of longevity mutants identifies Afg3 as a mitochondrial determinant of cytoplasmic mRNA translation and aging,” Aging Cell, vol. 12, no. 1, pp. 156–166, 2013.
  8. M. D. Brand, J. L. Pakay, A. Ocloo et al., “The basal proton conductance of mitochondria depends on adenine nucleotide translocase content,” Biochemical Journal, vol. 392, no. 2, pp. 353–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Endres, W. Neupert, and M. Brunner, “Transport of the ADP/ATP carrier of mitochondria from the TOM complex to the TIM22.54 complex,” EMBO Journal, vol. 18, no. 12, pp. 3214–3221, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Pfanner, P. Hoeben, M. Tropschug, and W. Neupert, “The carboxyl-terminal two-thirds of the ADP/ATP carrier polypeptide contains sufficient information to direct translocation into mitochondria,” Journal of Biological Chemistry, vol. 262, no. 31, pp. 14851–14854, 1987. View at Scopus
  11. M. T. Ryan, H. Müller, and N. Pfanner, “Functional staging of ADP/ATP carrier translocation across the outer mitochondrial membrane,” Journal of Biological Chemistry, vol. 274, no. 29, pp. 20619–20627, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Palmieri, “The mitochondrial transporter family (SLC25): physiological and pathological implications,” Pflugers Archiv European Journal of Physiology, vol. 447, no. 5, pp. 689–709, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Wohlrab, “The human mitochondrial transport protein family: identification and protein regions significant for transport function and substrate specificity,” Biochimica et Biophysica Acta, vol. 1709, no. 2, pp. 157–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Duszyński, K. Bogucka, G. Letko, U. Küster, W. Kunz, and L. Wojtczak, “Relationship between the energy cost of ATP transport and ATP synthesis in mitochondria,” Biochimica et Biophysica Acta, vol. 637, no. 2, pp. 217–223, 1981. View at Scopus
  15. S. E. Levy, Y.-S. Chen, B. H. Graham, and D. C. Wallace, “Expression and sequence analysis of the mouse adenine nucleotide translocase 1 and 2 genes,” Gene, vol. 254, no. 1-2, pp. 57–66, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Stepien, A. Torroni, A. B. Chung, J. A. Hodge, and D. C. Wallace, “Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation,” Journal of Biological Chemistry, vol. 267, no. 21, pp. 14592–14597, 1992. View at Scopus
  17. A. Chevrollier, D. Leiseau, and G. Stepien, “What is the specific role of ANT2 in cancer cells?” Medecine/Sciences, vol. 21, no. 2, pp. 156–161, 2005. View at Scopus
  18. J. V. Brower, N. Rodic, T. Seki et al., “Evolutionarily conserved mammalian adenine nucleotide translocase 4 is essential for spermatogenesis,” Journal of Biological Chemistry, vol. 282, no. 40, pp. 29658–29666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Klingenberg, “The ADP and ATP transport in mitochondria and its carrier,” Biochimica et Biophysica Acta, vol. 1778, no. 10, pp. 1978–2021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Saraste and J. E. Walker, “Internal sequence repeats and the path of polypeptide in mitochondrial ADP/ATP translocase,” FEBS Letters, vol. 144, no. 2, pp. 250–254, 1982. View at Scopus
  21. J. E. Walker and M. J. Runswick, “The mitochondrial transport protein superfamily,” Journal of Bioenergetics and Biomembranes, vol. 25, no. 5, pp. 435–446, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Brandolin, A. le Saux, V. Trezeguet, G. J. M. Lauquin, and P. V. Vignais, “Chemical, immunological, enzymatic, and genetic approaches to studying the arrangement of the peptide chain of the ADP/ATP carrier in the mitochondrial membrane,” Journal of Bioenergetics and Biomembranes, vol. 25, no. 5, pp. 459–472, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Riccio, H. Aquila, and M. Klingenberg, “Purification of the carboxy atractylate binding protein from mitochondria,” FEBS Letters, vol. 56, no. 1, pp. 133–138, 1975. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Aquila, W. Eiermann, W. Babel, and M. Klingenberg, “Isolation of the ADP/ATP translocator from beef heart mitochondria as the bongkrekate-protein complex,” The European Journal of Biochemistry, vol. 85, no. 2, pp. 549–560, 1978. View at Scopus
  25. E. Pebay-Peyroula, C. Dahout-Gonzalez, R. Kahn, V. Trézéguet, G. J.-M. Lauquin, and G. Brandolin, “Structure of mitochondrial ADP/ATP carrier in complex with carboxyatractyloside,” Nature, vol. 426, no. 6962, pp. 39–44, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Rey, P. Man, B. Clémençon et al., “Conformational dynamics of the bovine mitochondrial ADP/ATP carrier isoform 1 revealed by hydrogen/deuterium exchange coupled to mass spectrometry,” Journal of Biological Chemistry, vol. 285, no. 45, pp. 34981–34990, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Clémençon, M. Rey, V. Trézé, E. Forests, and L. Pelosis, “Yeast ADP/ATP carrier isoform 2: conformational dynamics and role of the RRRMMM signature sequence methionines,” Journal of Biological Chemistry, vol. 286, no. 41, pp. 36119–36131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Nury, C. Dahout-Gonzalez, V. Trézéguet, G. J. M. Lauquin, G. Brandolin, and E. Pebay-Peyroula, “Relations between structure and function of the mitochondrial ADP/ATP carrier,” Annual Review of Biochemistry, vol. 75, pp. 713–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Heidkämper, V. Müller, D. R. Nelson, and M. Klingenberg, “Probing the role of positive residues in the ADP/ATP carrier from yeast. The effect of six arginine mutations on transport and the four ATP versus ADP exchange modes,” Biochemistry, vol. 35, no. 50, pp. 16144–16152, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. S. D. Dyall, S. C. Agius, C. de Marcos Lousa, V. Trézéguet, and K. Tokatlidis, “The dynamic dimerization of the yeast ADP/ATP carrier in the inner mitochondrial membrane is affected by conserved cysteine residues,” Journal of Biological Chemistry, vol. 278, no. 29, pp. 26757–26764, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Hackenberg and M. Klingenberg, “Molecular weight and hydrodynamic parameters of the adenosine 5′-diphosphate-adenosine 5′-triphosphate carrier in triton X-100,” Biochemistry, vol. 19, no. 3, pp. 548–555, 1980. View at Scopus
  32. M. R. Block, G. Zaccaï, G. J. M. Lauquin, and P. V. Vignais, “Small angle neutron scattering of the mitochondrial ADP ATP carrier protein in detergent,” Biochemical and Biophysical Research Communications, vol. 109, no. 2, pp. 471–477, 1982. View at Scopus
  33. M. Hashimoto, E. Majima, S. Goto, Y. Shinohara, and H. Terada, “Fluctuation of the first loop facing the matrix of the mitochondrial ADP/ATP carrier deduced from intermolecular cross-linking of Cys56 residues by bifunctional dimaleimides,” Biochemistry, vol. 38, no. 3, pp. 1050–1056, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Kihira, E. Majima, Y. Shinohara, and H. Terada, “Cysteine labeling studies detect conformational changes in region 106-132 of the mitochondrial ADP/ATP carrier of Saccharomyces cerevisiae,” Biochemistry, vol. 44, no. 1, pp. 184–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Majima, K. Ikawa, M. Takeda, M. Hashimoto, Y. Shinohara, and H. Terada, “Translocation of loops regulates transport activity of mitochondrial ADP/ATP carrier deduced from formation of a specific intermolecular disulfide bridge catalyzed by copper-o-phenanthroline,” Journal of Biological Chemistry, vol. 270, no. 49, pp. 29548–29554, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Trézéguet, A. le Saux, C. David et al., “A covalent tandem dimer of the mitochondrial ADP/ATP carrier is functional in vivo,” Biochimica et Biophysica Acta, vol. 1457, no. 1-2, pp. 81–93, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Hatanaka, M. Hashimoto, E. Majima, Y. Shinohara, and H. Terada, “Functional expression of the tandem-repeated homodimer of the mitochondrial ADP/ATP carrier in Saccharomyces cerevisiae,” Biochemical and Biophysical Research Communications, vol. 262, no. 3, pp. 726–730, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-G. Huang, S. Odoy, and M. Klingenberg, “Chimers of two fused ADP/ATP carrier monomers indicate a single channel for ADP/ATP transport,” Archives of Biochemistry and Biophysics, vol. 394, no. 1, pp. 67–75, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Bamber, D.-J. Slotboom, and E. R. S. Kunji, “Yeast mitochondrial ADP/ATP carriers are monomeric in detergents as demonstrated by differential affinity purification,” Journal of Molecular Biology, vol. 371, no. 2, pp. 388–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. E. R. S. Kunji and P. G. Crichton, “Mitochondrial carriers function as monomers,” Biochimica et Biophysica Acta, vol. 1797, no. 6-7, pp. 817–831, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. R. Hunter and R. A. Haworth, “The Ca2+-induced membrane transition in mitochondria. The protective mechanisms,” Archives of Biochemistry and Biophysics, vol. 195, no. 2, pp. 453–459, 1979. View at Scopus
  42. R. A. Haworth and D. R. Hunter, “The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site,” Archives of Biochemistry and Biophysics, vol. 195, no. 2, pp. 460–467, 1979. View at Scopus
  43. P. Bernardi, K. M. Broekemeier, and D. R. Pfeiffer, “Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane,” Journal of Bioenergetics and Biomembranes, vol. 26, no. 5, pp. 509–517, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Zoratti and I. Szabo, “The mitochondrial permeability transition,” Biochimica et Biophysica Acta, vol. 1241, no. 2, pp. 139–176, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Brust, B. Daum, C. Breunig, A. Hamann, W. Kühlbrandt, and H. D. Osiewacz, “Cyclophilin D links programmed cell death and organismal aging in Podospora anserina,” Aging Cell, vol. 9, no. 5, pp. 761–775, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Woodfield, A. Rück, D. Brdiczka, and A. P. Halestrap, “Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition,” Biochemical Journal, vol. 336, no. 2, pp. 287–290, 1998. View at Scopus
  47. M. Crompton, S. Virji, and J. M. Ward, “Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore,” The European Journal of Biochemistry, vol. 258, no. 2, pp. 729–735, 1998. View at Scopus
  48. J. E. Kokoszka, K. G. Waymire, S. E. Levy et al., “The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore,” Nature, vol. 427, no. 6973, pp. 461–465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Giorgio, S. von Stockum, M. Antoniel et al., “Dimers of mitochondrial ATP synthase form the permeability transition pore,” Proceedings of the National Academy of Sciences, vol. 110, no. 15, pp. 5887–5892, 2013.
  50. M. Bonora, A. Bononi, E. de Marchi et al., “Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition,” Cell Cycle, vol. 12, no. 4, pp. 674–683, 2013.
  51. C. Pereira, N. Camougrand, S. Manon, M. J. Sousa, and M. Côrte-Real, “ADP/ATP carrier is required for mitochondrial outer membrane permeabilization and cytochrome c release in yeast apoptosis,” Molecular Microbiology, vol. 66, no. 3, pp. 571–582, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Pereira, S. Chaves, S. Alves et al., “Mitochondrial degradation in acetic acid-induced yeast apoptosis: the role of Pep4 and the ADP/ATP carrier,” Molecular Microbiology, vol. 76, no. 6, pp. 1398–1410, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Pereira, F. Azevedo, A. Rego, M. J. Sousa, S. R. Chaves, and M. Corte-Real, “The protective role of yeast Cathepsin D in acetic acid-induced apoptosis depends on ANT, (Aac2p) but not on the voltage-dependent channel (Por1p),” FEBS Letters, vol. 587, no. 2, pp. 200–205, 2013.
  54. B. H. Graham, K. G. Waymire, B. Cottrell, I. A. Trounce, G. R. MacGregor, and D. C. Wallace, “A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator,” Nature Genetics, vol. 16, no. 3, pp. 226–234, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Z. Jordens, L. Palmieri, M. Huizing et al., “Adenine nucleotide translocator 1 deficiency associated with Sengers syndrome,” Annals of Neurology, vol. 52, no. 1, pp. 95–99, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. J. D. Sharer, “The adenine nucleotide translocase type 1 (ANT1): a new factor in mitochondrial disease,” IUBMB Life, vol. 57, no. 9, pp. 607–614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. J. A. Mayr, T. B. Haack, E. Graf et al., “Lack of the mitochondrial protein acylglycerol kinase causes sengers syndrome,” The American Journal of Human Genetics, vol. 90, no. 2, pp. 314–320, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. K. A. Strauss, L. Dubiner, M. Simon et al., “Severity of cardiomyopathy associated with adenine nucleotide translocator-1 deficiency correlates with mtDNA haplogroup,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 9, pp. 3453–3458, 2013.
  59. G. W. Padberg, P. W. Lunt, M. Koch, and M. Fardeau, “Diagnostic criteria for facioscapulohumeral muscular dystrophy,” Neuromuscular Disorders, vol. 1, no. 4, pp. 231–234, 1991. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Wijmenga, J. E. Hewitt, L. A. Sandkuijl et al., “Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy,” Nature Genetics, vol. 2, no. 1, pp. 26–30, 1992. View at Scopus
  61. D. Gabellini, M. R. Green, and R. Tupler, “Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle,” Cell, vol. 110, no. 3, pp. 339–348, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. S. M. van der Maarel and R. R. Frants, “The D4Z4 repeat-mediated pathogenesis of facioscapulohumeral muscular dystrophy,” The American Journal of Human Genetics, vol. 76, no. 3, pp. 375–386, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. R. J. L. F. Lemmers, P. J. van der Vliet, R. Klooster et al., “A unifying genetic model for facioscapulohumeral muscular dystrophy,” Science, vol. 329, no. 5999, pp. 1650–1653, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Gabellini, G. D'Antona, M. Moggio et al., “Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1,” Nature, vol. 439, no. 7079, pp. 973–977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Laoudj-Chenivesse, G. Carnac, C. Bisbal et al., “Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle,” Journal of Molecular Medicine, vol. 83, no. 3, pp. 216–224, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Clemencon, M. Babot, and V. Trezeguet, “The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction,” Molecular Aspects of Medicine, vol. 34, no. 2-3, pp. 485–493, 2013.
  67. M. le Bras, A. Borgne-Sanchez, Z. Touat et al., “Chemosensitization by knockdown of adenine nucleotide translocase-2,” Cancer Research, vol. 66, no. 18, pp. 9143–9152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Moreno-Sanchez, S. Rodriguez-Enriquez, A. Marin-Hernandez, and E. Saavedra, “Energy metabolism in tumor cells,” FEBS Journal, vol. 274, no. 6, pp. 1393–1418, 2007.
  69. M.-F. Giraud and J. Velours, “The absence of the mitochondrial ATP synthase δ subunit promotes a slow growth phenotype of rho- yeast cells by a lack of assembly of the catalytic sector F1,” The European Journal of Biochemistry, vol. 245, no. 3, pp. 813–818, 1997. View at Scopus
  70. X. J. Chen and G. D. Clark-Walker, “Specific mutations in α and γ-subunits of F1-ATPase affect mitochondrial genome integrity in the petite-negative yeast Kluyveromyces lactis,” EMBO Journal, vol. 14, no. 13, pp. 3277–3286, 1995. View at Scopus
  71. X. J. Chen and G. D. Clark-Walker, “The mitochondrial genome integrity gene, MGI1, of Kluyveromyces lactis encodes the β-subunit of F1-ATPase,” Genetics, vol. 144, no. 4, pp. 1445–1454, 1996. View at Scopus
  72. X. J. Chen and G. D. Clark-Walker, “The petite mutation in yeasts: 50 years on,” International Review of Cytology, vol. 194, pp. 197–238, 2000. View at Scopus
  73. A. Chevrollier, D. Loiseau, P. Reynier, and G. Stepien, “Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism,” Biochimica et Biophysica Acta, vol. 1807, no. 6, pp. 562–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Buchet and C. Godinot, “Functional F1-ATPase essential in maintaining growth and membrane potential of human mitochondrial DNA-depleted ρ°cells,” Journal of Biological Chemistry, vol. 273, no. 36, pp. 22983–22989, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Kaukonen, J. K. Juselius, V. Tiranti et al., “Role of adenine nucleotide translocator 1 in mtDNA maintenance,” Science, vol. 289, no. 5480, pp. 782–785, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Napoli, A. Bordoni, M. Zeviani et al., “A novel missense adenine nucleotide translocator-1 gene mutation in a greek adPEO family,” Neurology, vol. 57, no. 12, pp. 2295–2298, 2001. View at Scopus
  77. H. Komaki, T. Fukazawa, H. Houzen, K. Yoshida, I. Nonaka, and Y. Goto -I, “A novel D104G mutation in the adenine nucleotide translocator 1 gene in autosomal dominant progressive external ophthalmoplegia patients with mitochondrial DNA with multiple deletions.,” Annals of Neurology, vol. 51, no. 5, pp. 645–648, 2002. View at Publisher · View at Google Scholar
  78. G. van Goethem, B. Dermaut, A. Löfgren, J.-J. Martin, and C. van Broeckhoven, “Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions,” Nature Genetics, vol. 28, no. 3, pp. 211–212, 2001. View at Publisher · View at Google Scholar · View at Scopus
  79. J. N. Spelbrink, F. Y. Li, V. Tiranti et al., “Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria,” Nature Genetics, vol. 28, no. 3, pp. 223–231, 2001.
  80. M. Deschauer, G. Hudson, T. Müller, R. W. Taylor, P. F. Chinnery, and S. Zierz, “A novel ANT1 gene mutation with probable germline mosaicism in autosomal dominant progressive external ophthalmoplegia,” Neuromuscular Disorders, vol. 15, no. 4, pp. 311–315, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Palmieri, S. Alberio, I. Pisano et al., “Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy,” Human Molecular Genetics, vol. 14, no. 20, pp. 3079–3088, 2005. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. Kihira, A. Iwahashi, E. Majima, H. Terada, and Y. Shinohara, “Twisting of the second transmembrane α-helix of the mitochondrial ADP/ATP carrier during the transition between two carrier conformational states,” Biochemistry, vol. 43, no. 48, pp. 15204–15209, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Galassi, E. Lamantea, F. Invernizzi et al., “Additive effects of POLG1 and ANT1 mutations in a complex encephalomyopathy,” Neuromuscular Disorders, vol. 18, no. 6, pp. 465–470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. C. de Marcos Lousa, V. Trézéguet, A.-C. Dianoux, G. Brandolin, and G. J.-M. Lauquin, “The human mitochondrial ADP/ATP carriers: kinetic properties and biogenesis of wild-type and mutant proteins in the yeast S. cerevisiae,” Biochemistry, vol. 41, no. 48, pp. 14412–14420, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. F. Fontanesi, L. Palmieri, P. Scarcia et al., “Mutation in AAC2, equivalent to human adPEO-associated ANT1 mutations, lead to defective oxidative phosphorylation in Saccharomyces cerevisiae and affect mitochondrial DNA stability,” Human Molecular Genetics, vol. 13, no. 9, pp. 923–934, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Kawamata, V. Tiranti, J. Magrané, C. Chinopoulos, and G. Manfredi, “adPEO mutations in ANT1 impair ADP-ATP translocation in muscle mitochondria,” Human Molecular Genetics, vol. 20, no. 15, Article ID ddr200, pp. 2964–2974, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. X. J. Chen, “Induction of an unregulated channel by mutations in adenine nucleotide translocase suggests an explanation for human ophthalmoplegia,” Human Molecular Genetics, vol. 11, no. 16, pp. 1835–1843, 2002. View at Scopus
  88. X. Wang, K. Salinas, X. Zuo, B. Kucejova, and X. J. Chen, “Dominant membrane uncoupling by mutant adenine nucleotide translocase in mitochondrial diseases,” Human Molecular Genetics, vol. 17, no. 24, pp. 4036–4044, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. X. Wang, X. Zuo, B. Kucejova, and X. J. Chen, “Reduced cytosolic protein synthesis suppresses mitochondrial degeneration,” Nature Cell Biology, vol. 10, no. 9, pp. 1090–1097, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. R. El-Khoury and A. Sainsard-Chanet, “Suppression of mitochondrial DNA instability of autosomal dominant forms of progressive external ophthalmoplegia-associated ANT1 mutations in Podospora anserina,” Genetics, vol. 183, no. 3, pp. 861–871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Bratic and N.-G. Larsson, “The role of mitochondria in aging,” Journal of Clinical Investigation, vol. 123, no. 3, pp. 951–957, 2013.
  92. H. D. Osiewacz and D. Bernhardt, “Mitochondrial quality control: impact on aging and life span—a mini review,” Gerontology. In press.
  93. M. Breitenbach, S. M. Jazwinski, and P. Laun, “The retrograde response and other pathways of interorganelle communication in yeast replicative aging,” in Aging Research in Yeast, vol. 57, pp. 79–100, Springer, Amsterdam, The Netherlands, 2012.